Trial Profile
Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Autonomic-nervous-system-disorders
- Focus Therapeutic Use
- 26 Sep 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society
- 28 Nov 2014 New trial record